Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

TERT Promoter Mutations in Solitary Fibrous Tumor.

Demicco EG, Wani K, Ingram D, Wagner M, Maki RG, Rizzo A, Meeker A, Lazar AJ, Wang WL.

Histopathology. 2018 Jul 9. doi: 10.1111/his.13703. [Epub ahead of print]

PMID:
29985536
2.

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.

Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H, Niknafs N, White JR, Silberstein JL, Sullivan R, Dowling D, Harb R, Nirschl TR, Veeneman BA, Tomlins SA, Wang Y, Jendrisak A, Graf RP, Dittamore R, Carducci MA, Eisenberger MA, Haffner MC, Meeker AK, Eshleman JR, Luo J, Velculescu VE, Drake CG, Antonarakis ES.

Oncotarget. 2018 Jun 19;9(47):28561-28571. doi: 10.18632/oncotarget.25564. eCollection 2018 Jun 19.

3.

Racial differences in maternal and umbilical cord blood leukocyte telomere length and their correlations.

Weber KA, Heaphy CM, Joshu CE, Lu J, Rohrmann S, Bienstock JL, Agurs-Collins T, Meeker AK, Platz EA.

Cancer Causes Control. 2018 Aug;29(8):759-767. doi: 10.1007/s10552-018-1054-8. Epub 2018 Jul 6.

PMID:
29980985
4.

Association between statin drug use and peripheral blood leukocyte telomere length in the National Health and Nutrition Examination Survey 1999-2002: a cross-sectional study.

Tran PT, Meeker AK, Platz EA.

Ann Epidemiol. 2018 May 14. pii: S1047-2797(17)30938-9. doi: 10.1016/j.annepidem.2018.04.010. [Epub ahead of print]

PMID:
29853162
5.

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.

Diplas BH, He X, Brosnan-Cashman JA, Liu H, Chen LH, Wang Z, Moure CJ, Killela PJ, Loriaux DB, Lipp ES, Greer PK, Yang R, Rizzo AJ, Rodriguez FJ, Friedman AH, Friedman HS, Wang S, He Y, McLendon RE, Bigner DD, Jiao Y, Waitkus MS, Meeker AK, Yan H.

Nat Commun. 2018 May 25;9(1):2087. doi: 10.1038/s41467-018-04448-6.

6.

PD-L1 expression in medulloblastoma: an evaluation by subgroup.

Martin AM, Nirschl CJ, Polanczyk MJ, Bell WR, Nirschl TR, Harris-Bookman S, Phallen J, Hicks J, Martinez D, Ogurtsova A, Xu H, Sullivan LM, Meeker AK, Raabe EH, Cohen KJ, Eberhart CG, Burger PC, Santi M, Taube JM, Pardoll DM, Drake CG, Lim M.

Oncotarget. 2018 Apr 10;9(27):19177-19191. doi: 10.18632/oncotarget.24951. eCollection 2018 Apr 10.

7.

A unique telomere DNA expansion phenotype in human retinal rod photoreceptors associated with aging and disease.

Bell WR, Meeker AK, Rizzo A, Rajpara S, Rosenthal IM, Flores Bellver M, Aparicio Domingo S, Zhong X, Barber JR, Joshu CE, Canto-Soler MV, Eberhart CG, Heaphy CM.

Brain Pathol. 2018 Apr 18. doi: 10.1111/bpa.12618. [Epub ahead of print]

PMID:
29668072
8.

Cancer telomeres and white crows.

Meeker AK.

Am J Clin Exp Urol. 2018 Apr 1;6(2):93-100. eCollection 2018. Review.

9.

Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer.

Haffner MC, Guner G, Taheri D, Netto GJ, Palsgrove DN, Zheng Q, Guedes LB, Kim K, Tsai H, Esopi DM, Lotan TL, Sharma R, Meeker AK, Chinnaiyan AM, Nelson WG, Yegnasubramanian S, Luo J, Mehra R, Antonarakis ES, Drake CG, De Marzo AM.

Am J Pathol. 2018 Jun;188(6):1478-1485. doi: 10.1016/j.ajpath.2018.02.014. Epub 2018 Mar 22.

PMID:
29577933
10.

Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy.

Duffield AS, Ascierto ML, Anders RA, Taube JM, Meeker AK, Chen S, McMiller TL, Phillips NA, Xu H, Ogurtsova A, Berger AE, Pardoll DM, Topalian SL, Ambinder RF.

Blood Adv. 2017 Jul 21;1(17):1324-1334. doi: 10.1182/bloodadvances.2017007260. eCollection 2017 Jul 25.

11.

Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.

Ojalvo LS, Thompson ED, Wang TL, Meeker AK, Shih IM, Fader AN, Cimino-Mathews A, Emens LA.

Hum Pathol. 2018 Apr;74:135-147. doi: 10.1016/j.humpath.2017.12.010. Epub 2017 Dec 27.

PMID:
29288043
12.

Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells.

Joshu CE, Peskoe SB, Heaphy CM, Kenfield SA, Mucci LA, Giovannucci EL, Stampfer MJ, Yoon G, Lee TK, Hicks JL, De Marzo AM, Meeker AK, Platz EA.

Prostate. 2018 Feb;78(3):233-238. doi: 10.1002/pros.23462. Epub 2017 Nov 22.

PMID:
29164645
13.

Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.

Muroyama Y, Nirschl TR, Kochel CM, Lopez-Bujanda Z, Theodros D, Mao W, Carrera-Haro MA, Ghasemzadeh A, Marciscano AE, Velarde E, Tam AJ, Thoburn CJ, Uddin M, Meeker AK, Anders RA, Pardoll DM, Drake CG.

Cancer Immunol Res. 2017 Nov;5(11):992-1004. doi: 10.1158/2326-6066.CIR-17-0040. Epub 2017 Oct 2.

14.

MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer.

Baena-Del Valle JA, Zheng Q, Esopi DM, Rubenstein M, Hubbard GK, Moncaliano MC, Hruszkewycz A, Vaghasia A, Yegnasubramanian S, Wheelan SJ, Meeker AK, Heaphy CM, Graham MK, De Marzo AM.

J Pathol. 2018 Jan;244(1):11-24. doi: 10.1002/path.4980. Epub 2017 Nov 14.

15.

Evaluation of telomere length in human cardiac tissues using cardiac quantitative FISH.

Sharifi-Sanjani M, Meeker AK, Mourkioti F.

Nat Protoc. 2017 Sep;12(9):1855-1870. doi: 10.1038/nprot.2017.082. Epub 2017 Aug 17.

PMID:
28817123
16.

PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast.

Thompson ED, Taube JM, Asch-Kendrick RJ, Ogurtsova A, Xu H, Sharma R, Meeker A, Argani P, Emens LA, Cimino-Mathews A.

Mod Pathol. 2017 Nov;30(11):1551-1560. doi: 10.1038/modpathol.2017.79. Epub 2017 Jul 21.

PMID:
28731046
17.

Telomeres and telomerase in prostate cancer development and therapy.

Graham MK, Meeker A.

Nat Rev Urol. 2017 Oct;14(10):607-619. doi: 10.1038/nrurol.2017.104. Epub 2017 Jul 4. Review.

18.

Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate.

Brennen WN, Zhang B, Kulac I, Kisteman LN, Antony L, Wang H, Meeker AK, De Marzo AM, Garraway IP, Denmeade SR, Isaacs JT.

Oncotarget. 2017 Jul 18;8(29):46710-46727. doi: 10.18632/oncotarget.17362.

19.

Fibrin-associated EBV-positive Large B-Cell Lymphoma: An Indolent Neoplasm With Features Distinct From Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation.

Boyer DF, McKelvie PA, de Leval L, Edlefsen KL, Ko YH, Aberman ZA, Kovach AE, Masih A, Nishino HT, Weiss LM, Meeker AK, Nardi V, Palisoc M, Shao L, Pittaluga S, Ferry JA, Harris NL, Sohani AR.

Am J Surg Pathol. 2017 Mar;41(3):299-312. doi: 10.1097/PAS.0000000000000775.

PMID:
28195879
20.

Diagnosis of optic nerve sheath meningioma during optic nerve sheath decompression.

Meeker AR, Ko MW, Carruth BP, Strumpf KB, Bersani TA.

Orbit. 2017 Feb;36(1):35-38. doi: 10.1080/01676830.2017.1279648. Epub 2017 Feb 3.

PMID:
28156180
21.

Alterations of type II classical cadherin, cadherin-10 (CDH10), is associated with pancreatic ductal adenocarcinomas.

Jinawath N, Shiao MS, Norris A, Murphy K, Klein AP, Yonescu R, Iacobuzio-Donahue C, Meeker A, Jinawath A, Yeo CJ, Eshleman JR, Hruban RH, Brody JR, Griffin CA, Harada S.

Genes Chromosomes Cancer. 2017 May;56(5):427-435. doi: 10.1002/gcc.22447. Epub 2017 Mar 7.

PMID:
28124395
22.

Influence of In Utero Maternal and Neonate Factors on Cord Blood Leukocyte Telomere Length: Clues to the Racial Disparity in Prostate Cancer?

Weber KA, Heaphy CM, Rohrmann S, Gonzalez B, Bienstock JL, Agurs-Collins T, Platz EA, Meeker AK.

Prostate Cancer. 2016;2016:3691650. doi: 10.1155/2016/3691650. Epub 2016 Dec 14.

23.

Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer.

Koschmann C, Nunez FJ, Mendez F, Brosnan-Cashman JA, Meeker AK, Lowenstein PR, Castro MG.

Cancer Res. 2017 Jan 15;77(2):227-233. doi: 10.1158/0008-5472.CAN-16-2301. Epub 2017 Jan 6. Review.

24.

Differential long-term stability of microRNAs and RNU6B snRNA in 12-20 year old archived formalin-fixed paraffin-embedded specimens.

Peskoe SB, Barber JR, Zheng Q, Meeker AK, De Marzo AM, Platz EA, Lupold SE.

BMC Cancer. 2017 Jan 6;17(1):32. doi: 10.1186/s12885-016-3008-4.

25.

Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and In Situ Hybridization.

Holdhoff M, Guner G, Rodriguez FJ, Hicks JL, Zheng Q, Forman MS, Ye X, Grossman SA, Meeker AK, Heaphy CM, Eberhart CG, De Marzo AM, Arav-Boger R.

Clin Cancer Res. 2017 Jun 15;23(12):3150-3157. doi: 10.1158/1078-0432.CCR-16-1490. Epub 2016 Dec 29.

26.

Low p16INK4a Expression in Early Passage Human Prostate Basal Epithelial Cells Enables Immortalization by Telomerase Expression Alone.

Graham MK, Principessa L, Antony L, Meeker AK, Isaacs JT.

Prostate. 2017 Mar;77(4):374-384. doi: 10.1002/pros.23276. Epub 2016 Nov 8.

27.

MUC1-ARF-A Novel MUC1 Protein That Resides in the Nucleus and Is Expressed by Alternate Reading Frame Translation of MUC1 mRNA.

Chalick M, Jacobi O, Pichinuk E, Garbar C, Bensussan A, Meeker A, Ziv R, Zehavi T, Smorodinsky NI, Hilkens J, Hanisch FG, Rubinstein DB, Wreschner DH.

PLoS One. 2016 Oct 21;11(10):e0165031. doi: 10.1371/journal.pone.0165031. eCollection 2016.

28.

Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.

Kim JY, Brosnan-Cashman JA, An S, Kim SJ, Song KB, Kim MS, Kim MJ, Hwang DW, Meeker AK, Yu E, Kim SC, Hruban RH, Heaphy CM, Hong SM.

Clin Cancer Res. 2017 Mar 15;23(6):1598-1606. doi: 10.1158/1078-0432.CCR-16-1147. Epub 2016 Sep 23.

29.

Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.

Cocks M, Taheri D, Ball MW, Bezerra SM, Del Carmen Rodriguez M, Ricardo BFP, Bivalacqua TJ, Sharma RB, Meeker A, Chaux A, Burnett AL, Netto GJ.

Hum Pathol. 2017 Jan;59:55-61. doi: 10.1016/j.humpath.2016.09.003. Epub 2016 Sep 20.

PMID:
27663086
30.

Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors.

Cives M, Ghayouri M, Morse B, Brelsford M, Black M, Rizzo A, Meeker A, Strosberg J.

Endocr Relat Cancer. 2016 Sep;23(9):759-67. doi: 10.1530/ERC-16-0147.

31.

Development and Application of a Novel Model System to Study "Active" and "Passive" Tumor Targeting.

Mukherjee A, Kumar B, Hatano K, Russell LM, Trock BJ, Searson PC, Meeker AK, Pomper MG, Lupold SE.

Mol Cancer Ther. 2016 Oct;15(10):2541-2550. Epub 2016 Aug 2.

32.

The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder.

Baras AS, Drake C, Liu JJ, Gandhi N, Kates M, Hoque MO, Meeker A, Hahn N, Taube JM, Schoenberg MP, Netto G, Bivalacqua TJ.

Oncoimmunology. 2016 Feb 18;5(5):e1134412. doi: 10.1080/2162402X.2015.1134412. eCollection 2016 May.

33.

Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.

Hackeng WM, Brosens LA, Poruk KE, Noë M, Hosoda W, Poling JS, Rizzo A, Campbell-Thompson M, Atkinson MA, Konukiewitz B, Klöppel G, Heaphy CM, Meeker AK, Wood LD.

Hum Pathol. 2016 Oct;56:93-100. doi: 10.1016/j.humpath.2016.06.006. Epub 2016 Jun 21.

PMID:
27342911
34.

Pediatric and adult vision restoration after optic nerve sheath decompression for idiopathic intracranial hypertension.

Bersani TA, Meeker AR, Sismanis DN, Carruth BP.

Orbit. 2016 Jun;35(3):132-9. doi: 10.1080/01676830.2016.1176051. Epub 2016 May 10.

PMID:
27163674
35.

Timing of pivotal clinical trial results reporting for newly approved medications varied by reporting source.

Withycombe B, Ovenell M, Meeker A, Ahmed SM, Hartung DM.

J Clin Epidemiol. 2016 Sep;77:78-83. doi: 10.1016/j.jclinepi.2016.04.007. Epub 2016 Apr 22.

PMID:
27108488
36.

High-resolution telomere fluorescence in situ hybridization reveals intriguing anomalies in germ cell tumors.

Shekhani MT, Barber JR, Bezerra SM, Heaphy CM, Gonzalez Roibon ND, Taheri D, Reis LO, Guner G, Joshu CE, Netto GJ, Meeker AK.

Hum Pathol. 2016 Aug;54:106-12. doi: 10.1016/j.humpath.2016.03.015. Epub 2016 Apr 13.

PMID:
27085557
37.

Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells.

Suryo Rahmanto Y, Jung JG, Wu RC, Kobayashi Y, Heaphy CM, Meeker AK, Wang TL, Shih IeM.

J Biol Chem. 2016 Apr 29;291(18):9690-9. doi: 10.1074/jbc.M115.707612. Epub 2016 Mar 7.

38.

ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.

Koschmann C, Calinescu AA, Nunez FJ, Mackay A, Fazal-Salom J, Thomas D, Mendez F, Kamran N, Dzaman M, Mulpuri L, Krasinkiewicz J, Doherty R, Lemons R, Brosnan-Cashman JA, Li Y, Roh S, Zhao L, Appelman H, Ferguson D, Gorbunova V, Meeker A, Jones C, Lowenstein PR, Castro MG.

Sci Transl Med. 2016 Mar 2;8(328):328ra28. doi: 10.1126/scitranslmed.aac8228.

39.

The immune microenvironment of breast ductal carcinoma in situ.

Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN, Argani P, Cimino-Mathews A, Emens LA.

Mod Pathol. 2016 Mar;29(3):249-58. doi: 10.1038/modpathol.2015.158. Epub 2016 Jan 15.

40.

TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer.

Wong HY, Wang GM, Croessmann S, Zabransky DJ, Chu D, Garay JP, Cidado J, Cochran RL, Beaver JA, Aggarwal A, Liu ML, Argani P, Meeker A, Hurley PJ, Lauring J, Park BH.

Oncotarget. 2015 Dec 29;6(42):44927-40. doi: 10.18632/oncotarget.6743.

41.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HPV, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HMC, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M.

Semin Cancer Biol. 2015 Dec;35 Suppl:S276-S304. doi: 10.1016/j.semcancer.2015.09.007. Review.

42.

PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.

Cimino-Mathews A, Thompson E, Taube JM, Ye X, Lu Y, Meeker A, Xu H, Sharma R, Lecksell K, Cornish TC, Cuka N, Argani P, Emens LA.

Hum Pathol. 2016 Jan;47(1):52-63. doi: 10.1016/j.humpath.2015.09.003. Epub 2015 Sep 21.

43.

Leukocyte telomere length and its association with mammographic density and proliferative diagnosis among women undergoing diagnostic image-guided breast biopsy.

Bodelon C, Heaphy CM, Meeker AK, Geller B, Vacek PM, Weaver DL, Chicoine RE, Shepherd JA, Mahmoudzadeh AP, Patel DA, Brinton LA, Sherman ME, Gierach GL.

BMC Cancer. 2015 Oct 30;15:823. doi: 10.1186/s12885-015-1860-2.

44.

PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors.

Yang HP, Meeker A, Guido R, Gunter MJ, Huang GS, Luhn P, d'Ambrosio L, Wentzensen N, Sherman ME.

Cancer Causes Control. 2015 Dec;26(12):1729-36. doi: 10.1007/s10552-015-0666-5. Epub 2015 Sep 16.

45.

Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.

Martin AM, Nirschl TR, Nirschl CJ, Francica BJ, Kochel CM, van Bokhoven A, Meeker AK, Lucia MS, Anders RA, DeMarzo AM, Drake CG.

Prostate Cancer Prostatic Dis. 2015 Dec;18(4):325-32. doi: 10.1038/pcan.2015.39. Epub 2015 Aug 11.

46.

Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes.

Cochran RL, Cidado J, Kim M, Zabransky DJ, Croessmann S, Chu D, Wong HY, Beaver JA, Cravero K, Erlanger B, Parsons H, Heaphy CM, Meeker AK, Lauring J, Park BH.

Oncotarget. 2015 Sep 22;6(28):25240-51. doi: 10.18632/oncotarget.4595.

47.

Telomere length alterations unique to invasive lobular carcinoma.

Heaphy CM, Asch-Kendrick R, Argani P, Meeker AK, Cimino-Mathews A.

Hum Pathol. 2015 Aug;46(8):1197-203. doi: 10.1016/j.humpath.2015.05.001. Epub 2015 May 22.

PMID:
26092192
48.

Prediagnostic Obesity and Physical Inactivity Are Associated with Shorter Telomere Length in Prostate Stromal Cells.

Joshu CE, Peskoe SB, Heaphy CM, Kenfield SA, Van Blarigan EL, Mucci LA, Giovannucci EL, Stampfer MJ, Yoon G, Lee TK, Hicks JL, De Marzo AM, Meeker AK, Platz EA.

Cancer Prev Res (Phila). 2015 Aug;8(8):737-42. doi: 10.1158/1940-6207.CAPR-15-0097. Epub 2015 May 19.

49.

Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade.

Taube JM, Young GD, McMiller TL, Chen S, Salas JT, Pritchard TS, Xu H, Meeker AK, Fan J, Cheadle C, Berger AE, Pardoll DM, Topalian SL.

Clin Cancer Res. 2015 Sep 1;21(17):3969-76. doi: 10.1158/1078-0432.CCR-15-0244. Epub 2015 May 5.

50.

Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial.

Heaphy CM, Gaonkar G, Peskoe SB, Joshu CE, De Marzo AM, Lucia MS, Goodman PJ, Lippman SM, Thompson IM Jr, Platz EA, Meeker AK.

Prostate. 2015 Aug 1;75(11):1160-6. doi: 10.1002/pros.22997. Epub 2015 Apr 20.

Supplemental Content

Loading ...
Support Center